again, oxidative stress is believed to be the culprit, with decreased GSTO gene expression resulting in a lowered age of onset for the diseases
According to a However, the research admit their were limitations to their study and that further research is necessary to support its use
Conclusion Currently, there is a large population of NAFLD/NASH patients who require long-term treatment, yet there is only one approved drug specifically for NASH, Rezdiffra (resmetirom), indicating that the clinical need is far from being fully met
Vernstrm L, Gullaksen S, Srensen SS, Funck KL, Laugesen E, Poulsen PL
rushing the rate is the single most common error in non-medical settings
In December 2025, Novo Nordisk received FDA approval for an oral formulation of Wegovy that demonstrated weight loss effects similar to those of the Wegovy injection